Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 43

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 43
---
2025 and 1,088,842 warrants also to be exercised at the time of Closing. The loan agreements entered on October 16, 2023, from several shareholders include warrants that will be granted to the lenders upon conversion of the loan into shares. The non -marketablewarrants will be issued at a rate equal to 125% of the total loan conversion shares outstanding at the effective time of conversion. The exercise price of the warrants will be equal to a rate of 110% of the conversion share price, and the exercise period will be 42 months from the date of their issuance; (A)Adjustment for $1,081,257 related to conversion of loans from related parties as noted above at the Closing; (A)Adjustment for $1,115,065 related to conversion of loans from related parties as noted above at the Closing; (A)Adjustment for $11,662,604 related to conversion of convertible loan and warrants as noted above at the Closing; 27 (A)Adjustment to remove $9,923,013 of non -cashrevaluation expense of convertible loans from shareholders and related parties related to loans converted as noted above at the Closing as if the Merger took place on January 1, 2025, for the six months ended June 30, 2025; (A)Adjustment to remove $5,043,728 of non -cashrevaluation expense of convertible loans from shareholders and related parties related to loans converted as noted above at the Closing as if the Merger took place January 1, 2024, for the twelve months ended December 31, 2024; (B)Adjustment to record additional non -recurringNLS transaction costs of approximately $350,000 for legal, audit and other professional service provider expenses and director and officer tail insurance that were not included as part of the transaction costs recorded as of June 30, 2025, for $420,289. For the transaction costs incurred and recorded subsequent to June 30, 2025, $200,000 has been paid in cash and $150,000 has been accrued for purposes of payment subsequent to the Closing; (B)Adjustment to record additional non -recurringKadimastem transaction costs of approximately $150,000 for legal, audit and other professional service provider expenses that were not incurred or accrued as of June 30, 2025, of $100,889. For the transaction costs incurred and recorded subsequent